BioNTech SE is a biotechnology company based in Mainz, Germany, specializing in the research, development, and marketing of immunological and RNA-based medicines. The company addresses serious diseases such as cancer and infectious diseases through innovative therapeutic approaches. With the acquisition of CureVac SE, BioNTech strengthens its technological foundation in mRNA design and delivery formulations. Strategically, the company aims to establish itself as a commercial entity with multiple approved products by 2030.
Die Erforschung und Entwicklung, die Herstellung und die Vermarktung von immunologischen und von RNA-basierten Arzneimitteln und Testverfahren zur Diagnostik, Vorbeugung und Therapie von Krebserkrankungen, Infektionskrankheiten und anderen schwerwiegenden Krankheiten.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Mainz Local Court, HRB 48720 (as of 29 October 2026)
| Name | Type | City |
|---|---|---|
| Annemarie Hanekamp | Vorstand | Amstelveen |
| Kylie Jimenez | Vorstand | Mainz |
| Sierk Pötting | Vorstand | München |
| James Ryan | Vorstand | St Albans |
| Ugur Sahin | Vorstand | Mainz |
| Özlem Türeci | Vorstand | Mainz |
| Ramon Zapata Gomez | Vorstand | Mainz |
| Company | Location |
|---|---|
 BioNTech BioNTainer Holding GmbH | Mainz |
| BioNTech Cell & Gene Therapies GmbH | Mainz |
| BioNTech Collaborations GmbH | Mainz |
Source: German Commercial Register (Handelsregister) Mainz Local Court, HRB 48720 (as of 29 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €2,869,900,000 | €930,300,000 | €21,988,600,000 | — |
| 2024 | €2,751,100,000 | €930,300,000 | €22,529,700,000 | 6,946 |
| 2023 | — | — | €23,006,300,000 | 6,292 |
| 2022 | — | — | €23,279 | 4,692 |
| 2021 | — | — | €15,831 | 3,138 |
| 2020 | — | — | €2,318,620,000 | 2,047 |
| 2019 | €108,589 | — | €797,647,000 | 1,323 |
| 2018 | €127,575,000 | -€48,262,000 | €652,986,000 | 1,026 |
| 2017 | €61,598,000 | -€85,950,000 | €389,959,000 | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Mainz Local Court, HRB 48720 (as of 29 October 2026)
PAION AG
Aachen · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
Grünenthal Pharma GmbH & Co. Kommanditgesellschaft
Aachen · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
STADA Arzneimittel Aktiengesellschaft
Bad Vilbel · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
| Cost type | Amount | Share |
|---|---|---|
| Cost of Goods Sold | €13,690,000 | 7.5% |
| Admin Costs | €26,334,000 | 14.4% |
| R&D Costs | €143,040,000 | 78.1% |
